Conclusion
This study emphasis that diffuse alveolar damage and microvascular
pulmonary thrombosis in SARS-CoV-2 patients caused by either direct
viral cytopathic effect or host immune and inflammatory reaction. Due to
severe hypoxemia in COVID-19 patients suffering ARDS, appropriate oxygen
support and anticoagulation therapy with strict monitoring is
recommended.
Key words: COVID-19, diffuse alveolar damage, biopsy, thrombosis